Article
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.
ESMO open - 1 Aug 2023
Garon E B, Reck M, Nishio K, Heymach J V, Nishio M, Novello S, Paz-Ares L, Popat S, Aix S Ponce, Graham H, Butts B D, Visseren-Grul C, Nakagawa K
Abstract excerpt
BACKGROUND: Ramucirumab plus erlotinib (RAM + ERL) demonstrated superior progression-free survival (PFS) over placebo + ERL (PBO + ERL) in the phase III RELAY study of patients with epidermal growth factor receptor (EGFR)-mutated metastatic non-small-cell lung cancer (EGFR+ mNSCLC; NCT02411448). Next-generation sequencing (NGS) was used to identify clinically relevant alterations in circulating tumor DNA (ctDNA)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.